Riperidone

PreclinicalSmall molecule

UUniversity of Alabama at Birmingham

Riperidone is one of 5 small molecule programs targeting Suicidal Ideation. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Suicidal IdeationActive, not recruiting

Suicidal IdeationPreclinical

Active, not recruiting

Competition

Competitive Landscape

4 competitors in Suicidal Ideation

#DrugCompanyPhaseTrials

Ketalar

AAultman Health Foundation

Approved

13 2

Minipress

Pfizer

Approved

1 3

Versed

CConrado Roberto Hoffmann Filho

Approved

2 4

Ketalar

Boehringer Ingelheim

Phase 3

6 5

Riperidone

UUniversity of Alabama at Birmingham

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Suicidal Ideation1 trial

Impulsivity and Thought Process Disorder in Patients With Active Suicidal Ideation and Depression

Withdrawn·UUniversity of Alabama at Birmingham·N/A·NCT01770600

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Riperidone. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Riperidone compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Riperidone. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Alabama at Birmingham company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: UUniversity of Alabama at Birmingham

Riperidone

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Suicidal Ideation1 trial

References

Drug Info

Quick Facts

Related News